Pierre Péterlin

3.8k total citations
108 papers, 1.0k citations indexed

About

Pierre Péterlin is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Pierre Péterlin has authored 108 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Hematology, 43 papers in Oncology and 31 papers in Immunology. Recurrent topics in Pierre Péterlin's work include Hematopoietic Stem Cell Transplantation (40 papers), Acute Myeloid Leukemia Research (38 papers) and Immune Cell Function and Interaction (17 papers). Pierre Péterlin is often cited by papers focused on Hematopoietic Stem Cell Transplantation (40 papers), Acute Myeloid Leukemia Research (38 papers) and Immune Cell Function and Interaction (17 papers). Pierre Péterlin collaborates with scholars based in France, United States and Canada. Pierre Péterlin's co-authors include Patrice Chevallier, Thierry Guillaume, Alice Garnier, Philippe Moreau, Marie C. Béné, Amandine Le Bourgeois, Mohamad Mohty, Steven Le Gouill, Thomas Gastinne and Nicolas Blin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Pierre Péterlin

99 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre Péterlin France	18	670	347	313	170	154	108	1.0k
Rémy Duléry France	17	489 0.7×	346 1.0×	196 0.6×	187 1.1×	122 0.8×	89	935
Usama Gergis United States	18	538 0.8×	427 1.2×	141 0.5×	198 1.2×	128 0.8×	112	975
Pascual Balsalobre Spain	17	462 0.7×	252 0.7×	141 0.5×	102 0.6×	97 0.6×	57	782
Federica Galaverna Italy	15	581 0.9×	333 1.0×	267 0.9×	57 0.3×	88 0.6×	48	867
Xavier Poiré Belgium	17	505 0.8×	401 1.2×	186 0.6×	197 1.2×	54 0.4×	69	971
Roni Tamari United States	18	601 0.9×	278 0.8×	99 0.3×	161 0.9×	135 0.9×	98	977
Kavita Raj United Kingdom	19	903 1.3×	255 0.7×	330 1.1×	212 1.2×	64 0.4×	62	1.2k
Jason Butler Australia	12	595 0.9×	210 0.6×	330 1.1×	83 0.5×	57 0.4×	43	900
Haris Ali United States	15	701 1.0×	227 0.7×	241 0.8×	166 1.0×	89 0.6×	101	953
Kellie Sprague United States	14	540 0.8×	284 0.8×	250 0.8×	117 0.7×	57 0.4×	30	903

Countries citing papers authored by Pierre Péterlin

Since Specialization

Citations

This map shows the geographic impact of Pierre Péterlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Péterlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Péterlin more than expected).

Fields of papers citing papers by Pierre Péterlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Péterlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Péterlin. The network helps show where Pierre Péterlin may publish in the future.

Co-authorship network of co-authors of Pierre Péterlin

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Péterlin. A scholar is included among the top collaborators of Pierre Péterlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Péterlin. Pierre Péterlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garciaz, Sylvain, Pierre Péterlin, Daniel Morillo, et al.. (2025). γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction. Blood. 146(Supplement 1). 652–652.

Chevallier, Patrice, Anne C. M. Thiébaut, Sylvie François, et al.. (2025). A phase II study of ponatinib for prevention of relapse after allotransplantation in <i>FLT3</i> internal tandem duplication mutation positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial. Haematologica. 110(10). 2525–2529. 1 indexed citations

Garcia, Jacqueline S., Uwe Platzbecker, Olatoyosi Odenike, et al.. (2024). Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 145(11). 1126–1135. 7 indexed citations

Maiti, Abhishek, Pierre Péterlin, Daniel Morillo, et al.. (2024). ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Blood. 144(Supplement 1). 2876–2876. 1 indexed citations

Péterlin, Pierre, Alice Garnier, Amandine Le Bourgeois, et al.. (2024). Successful Treatment of Congenital Erythropoietic Porphyria Using Matched Unrelated Hematopoietic Stem Cell Transplantation in an Adult: A Case Report. SHILAP Revista de lepidopterología. 4(2). e342–e342. 1 indexed citations

Bris, Yannick Le, Catherine Godon, Olivier Pichon, et al.. (2023). Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms. Blood. 142(Supplement 1). 6051–6051.

Péterlin, Pierre, Alice Garnier, Amandine Le Bourgeois, et al.. (2023). Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial. EClinicalMedicine. 64. 102254–102254. 5 indexed citations

Riou, Jérémie, Pierre Péterlin, Tony Marchand, et al.. (2022). Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study. Leukemia. 36(10). 2408–2417. 4 indexed citations

Devillier, Raynier, Édouard Forcade, Alice Garnier, et al.. (2021). In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Advances. 6(6). 1804–1812. 17 indexed citations

10.

Wei, Andrew H., Jacqueline S. Garcia, Uma Borate, et al.. (2019). A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome. Blood. 134(Supplement_1). 568–568. 39 indexed citations

11.

Bodet‐Milin, Caroline, Clément Bailly, Thierry Guillaume, et al.. (2018). Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. Biology of Blood and Marrow Transplantation. 25(5). 906–911. 3 indexed citations

12.

Péterlin, Pierre, Thierry Guillaume, Alice Garnier, et al.. (2018). Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases. Leukemia Research Reports. 9. 16–17. 1 indexed citations

13.

Bourcier, Jessie, Florent Morio, Thomas Gastinne, et al.. (2017). Prevalence of the reversed halo sign in neutropenic patients compared with non‐neutropenic patients: Data from a single‐centre study involving 27 patients with pulmonary mucormycosis (2003‐2016). Mycoses. 60(8). 526–533. 26 indexed citations

14.

Mohty, Mohamad, Florent Malard, Evelyne D’Incan, et al.. (2017). Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial. Blood. 130. 2624–2624. 5 indexed citations

15.

Tessoulin, Benoît, Thomas Gastinne, Philippe Moreau, et al.. (2017). Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas. Annals of Hematology. 96(6). 943–950. 9 indexed citations

16.

Péterlin, Pierre, Jacques Delaunay, Thierry Guillaume, et al.. (2014). Complete Donor T Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced-Intensity Conditioning Regimen Allogeneic Transplantation in Adults. Biology of Blood and Marrow Transplantation. 21(1). 180–184. 10 indexed citations

17.

Loirat, Marion, Patrice Chevallier, Christophe Leux, et al.. (2014). Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Annals of Oncology. 26(2). 386–392. 30 indexed citations

18.

Bourgeois, Amandine Le, Myriam Labopin, Thierry Guillaume, et al.. (2014). Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. Experimental Hematology. 42(11). 945–954. 11 indexed citations

19.

Tessoulin, Benoît, J. Delaunay, Patrice Chevallier, et al.. (2014). Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. Bone Marrow Transplantation. 49(4). 567–571. 46 indexed citations

20.

Bourgeois, Amandine Le, Catherine Mohr, Thierry Guillaume, et al.. (2013). Comparison of Outcomes after Two Standards-of-Care Reduced-Intensity Conditioning Regimens and Two Different Graft Sources for Allogeneic Stem Cell Transplantation in Adults with Hematologic Diseases: A Single-Center Analysis. Biology of Blood and Marrow Transplantation. 19(6). 934–939. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact